HUTCHMED(US:HCM) Huafu Securities·2026-02-01 11:59Investment Rating - The report maintains a rating of "Outperform" for the pharmaceutical sector, indicating a positive outlook compared to the broader market [7]. Core Insights - The PAM pathway represents a significant market opportunity, with a potential market size of approximately $10 billion, particularly relevant for breast and prostate cancers [4][13]. - Celcuity's Gedatolisib is highlighted as a promising PAM inhibitor, showing comparable efficacy to existing therapies and is expected to establish a new standard of care in HR+/HER2- breast cancer treatment [21][31]. - The report emphasizes the importance of innovation in the pharmaceutical sector, with a focus on drug development and the integration of advanced technologies [5]. Summary by Sections PAM Pathway Market Potential - The PAM pathway is underdeveloped in solid tumors, with mutations occurring in 38% of cancer patients, covering major types like breast and prostate cancer [4][14]. - Potential revenues from PAM inhibitors are comparable to CDK4/6 and AR therapies, estimated between $8 billion to $10 billion [4][18]. Celcuity and Gedatolisib - Gedatolisib has shown superior efficacy in preclinical studies, with a median progression-free survival (mPFS) of 9.3 months in combination therapy, significantly outperforming standard treatments [22][31]. - The FDA has accepted a new drug application for Gedatolisib, with a priority review status and a target decision date set for July 17, 2026 [31][32]. Hong Kong and Celcuity's Developments - Hong Kong's Hong Kong Medical Index has shown a decline, with specific stocks like Celcuity and Honghua Medicine being highlighted for their innovative approaches in targeting HER2 and PAM pathways [5][70]. - Honghua Medicine is developing a HER2-targeted PAM inhibitor, HMPL-A251, which has demonstrated strong anti-tumor activity in various models and is currently in clinical trials [33][41].